TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy (The University Of Texas MD Anderson Cancer Center)

N/A

Report date: 2026/04/24 20:01:59

Base Information

Drug NameTROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy (The University Of Texas MD Anderson Cancer Center)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy

Mechanisms of ActionTransforming growth factor beta receptor 2 modulatorsNatural killer cell replacementsTumor-associated calcium signal transducer 2 modulators

TargetsTransforming growth factor beta receptor 2Tumor-associated calcium signal transducer 2

Therapy Area/IndicationsNeoplasm MetastasisColorectal NeoplasmsCarcinoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesThe University Of Texas MD Anderson Cancer Center

China Registration ClassN/A

Develop Information

Active CompaniesThe University Of Texas MD Anderson Cancer Center

Inactive CompaniesN/A

Active IndicationsNeoplasm MetastasisColorectal NeoplasmsCarcinoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A